Rydex Biotechnology Inv

Frequently Asked Questions About RYOIX

What does RYOIX invest in?

Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

What is the expense ratio of RYOIX?

Rydex Biotechnology Inv (RYOIX) charges an expense ratio of 1.40%. This is the annual fee deducted from fund assets to cover management and operations.

How big is RYOIX?

Rydex Biotechnology Inv (RYOIX) manages $92.3M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is RYOIX actively managed or an index fund?

RYOIX's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was RYOIX launched?

Rydex Biotechnology Inv (RYOIX) launched in March 1998 and is managed by the fund issuer.

How has RYOIX performed?

RYOIX's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.